O. Sabri

Dissociation between striatal alpha4beta2 nicotinic acetylcholine receptors (alpha4beta2) and dopamine transporters (DAT) in Parkinson disease: A 2-[18F]-F-A-85380 PET/[123I]-FP-CIT SPECT study

S. Hesse, O. Sabri, H. Barthel, 2006, NeuroImage.

Current status and future role of brain PET/MRI in clinical and research settings

A. Drzezga, O. Sabri, H. Barthel, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Nicotinic acetylcholine receptors (alpha4beta2) and their relationship to cognitive and mood symptoms in Parkinson disease: A 2-[18F]-F-A-85380 PET study

M. Patt, Philipp Meyer, S. Hesse, 2006, NeuroImage.

Initial clinical results of simultaneous 18F-FDG PET/MRI in comparison to 18F-FDG PET/CT in patients with head and neck cancer

O. Sabri, R. Kluge, T. Kahn, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

Cerebral nicotinic acetylcholine receptors in patients with Alzheimer's disease assessed with 2-[18F]F-A85380 PET—correlations to dementia severity

Kai Kendziorra, M. Patt, S. Hesse, 2006, NeuroImage.

Norchloro-fluoro-homoepibatidine (NCFHEB) — A promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET

M. Patt, J. Steinbach, P. Brust, 2008, European Neuropsychopharmacology.

Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome

S. Hesse, O. Sabri, H. Barthel, 2006, Journal of Neural Transmission.

Reduced serotonin transporter–availability in obsessive–compulsive disorder (OCD)

U. Müller, M. Angermeyer, S. Hesse, 2004, European Archives of Psychiatry and Clinical Neuroscience.

Basal ganglia involvement of a patient with SCA 17

S. Hesse, O. Sabri, A. Storch, 2004, Journal of Neurology.